Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$1.19 CAD
Change Today +0.02 / 1.71%
Volume 32.4K
As of 3:59 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

immunovaccine inc (IMV) Snapshot

Open
C$1.17
Previous Close
C$1.17
Day High
C$1.19
Day Low
C$1.16
52 Week High
08/25/14 - C$1.40
52 Week Low
11/7/14 - C$0.56
Market Cap
109.2M
Average Volume 10 Days
236.4K
EPS TTM
C$-0.08
Shares Outstanding
91.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOVACCINE INC (IMV)

Related News

No related news articles were found.

immunovaccine inc (IMV) Related Businessweek News

No Related Businessweek News Found

immunovaccine inc (IMV) Details

Immunovaccine Inc., a clinical stage biopharmaceutical company, discovers and develops products that activate the immune system to treat cancer and prevent infectious diseases. The company develops its products based on the DepoVax vaccine-adjuvanting platform, which is a vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Its product pipeline includes DPX-Survivac, a therapeutic cancer vaccine, which has completed Phase I/Ib clinical trials for the treatment of ovarian cancer and is in Phase II clinical trials for the treatment of lymphoma cancer; DPX-0907, a therapeutic cancer vaccine that has completed Phase I/Ib clinical trials for the treatment of breast, ovarian, and prostate cancer; and DPX-RSV, which is in Phase I/Ib clinical trials for the treatment of respiratory diseases. The company also develops vaccines for infectious diseases, including bio-defense vaccines that would protect against anthrax and Ebola virus infection. In addition, it develops vaccine programs comprising addiction programs and animal health vaccine programs. Immunovaccine Inc. was founded in 2000 and is headquartered in Halifax, Canada.

23 Employees
Last Reported Date: 05/12/15
Founded in 2000

immunovaccine inc (IMV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: C$250.7K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$163.2K
Compensation as of Fiscal Year 2014.

immunovaccine inc (IMV) Key Developments

Immunovaccine Inc.'s DPX-Survivac Receives Orphan Drug Designation from FDA for the Treatment of Ovarian Cancer

Immunovaccine Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to DPX-Survivac for the treatment of ovarian cancer. This designation is valid for all applications of DPX-Survivac in ovarian cancer without restriction to a specific stage of disease. DPX-Survivac is the company's lead clinical-stage cancer immunotherapy. It activates and directs an immune response to the tumor antigen survivin, a protein that is found in tumors of more than 90% of ovarian cancer patients. DPX-Survivac was granted this status following a review by the FDA of pre-clinical and clinical data submitted by the Company. This data included the recently published Phase 1 data in advanced ovarian cancer, which demonstrated strong and durable immune responses in the majority of patients receiving DPX-Survivac in combination with low dose oral cyclophosphamide.

ImmunoVaccine Inc. and PharmAthene, Inc. Sign Exclusive Worldwide License Agreement to Develop and Commercialize an Anthrax Vaccine Formulated in DepoVax

ImmunoVaccine Inc. announced that it has entered into an exclusive worldwide license agreement with PharmAthene Inc. to develop and commercialize a Recombinant Protective Antigen Anthrax vaccine (rPA) candidate utilizing Immunovaccine's proprietary DepoVax vaccine platform. Under the terms of this agreement, PharmAthene will work exclusively with Immunovaccine to develop an adjuvanted non-alum based rPA vaccine. In return, Immunovaccine has granted PharmAthene exclusive worldwide rights to use DepoVaxTM for the development and commercialization of the novel single dose anthrax vaccine. Immunovaccine will receive annual payments of USD 200,000, payments of up to USD 8 million for the achievement of development, U.S. and international regulatory milestones, and initial product sales, and up to USD 42 million for the achievement of certain sales targets for a total of up to USD 50 million if all milestones are achieved. Additionally, Immunovaccine will receive a royalty on net sales and will not be responsible for product development costs.

ImmunoVaccine Inc. Reports Clinical Results with DPX-Survivac in Combination with an Immune-Modulating Compound

Immunovaccine Inc. announced that data from its completed Phase 1 clinical trial with cancer immunotherapy candidate, DPX-Survivac, was published in the peer reviewed journal Oncoimmunology. The manuscript "Survivin targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients, outlines the safety and immunogenicity of DPX-Survivac when combined with a low dose of cyclophosphamide taken orally by patients. This work shows that the combination immunotherapy of the DPX-Survivac vaccine and metronomic cyclophosphamide was highly immunogenic in individuals with high-risk ovarian cancer. Immune responses were generated in almost all study participants. Both high- magnitude and polyfunctional survivin-specific T cells were induced. These highly functional T cells produced several well-known activation markers and were detected in the blood of individuals with ovarian cancer as early as 21 days following vaccination. In a follow on study that will be published in the future, one patient with measurable and stable disease achieved a 43% reduction in tumor size, demonstrating a durable clinical benefit associated with the DPX-Survivac therapy. The Phase 1 study evaluated DPX-Survivac in combination with a maintenance low dose oral cyclophosphamide in individuals with ovarian cancer who have responded favorably to a standard of care platinum-based chemotherapy. The dose of cyclophosphamide was designed to have an immune modulation rather than a chemotherapeutic effect. Study participants were enrolled in a non-randomized, dose escalation fashion to receive three doses of DPX-Survivac alone or the vaccine along with cyclophosphamide. Almost all study participants receiving the therapy produced robust T cell responses, with the high responses appearing in participants who also received cyclophosphamide. The combination of DPX-Survivac and oral cyclophosphamide was generally well tolerated with no significant systemic adverse events.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMV:CN C$1.19 CAD +0.02

IMV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMV.
View Industry Companies
 

Industry Analysis

IMV

Industry Average

Valuation IMV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 16.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOVACCINE INC, please visit www.imvaccine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.